Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

AsclepiX Therapeutics

AsclepiX Therapeutics
PRIVATE STATUS
Later Stage VC LATEST DEAL TYPE
$5M LATEST DEAL AMOUNT
12 INVESTORS
Description

Provider of biomimetic anti-angiogenic and anti-lymphangiogenic peptides created to treat ocular diseases. The company develops biomimetic anti-angiogenic and anti-lymphangiogenic peptides for indications in ophthalmology, oncology and for other angiogenesi and lymphangiogenesis-dependent diseases enabling patients and doctors to better treat ocular ailments.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Other Pharmaceuticals and Biotechnology
Primary Office
  • 301 West 29th Street
  • Baltimore, MD 21211
  • United States

+1 (410) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore AsclepiX Therapeutics’s full profile, request a free trial.

AsclepiX Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 17-Jun-2019 $5M 00.00 Completed Generating Revenue
6. Grant 01-Jan-2017 00.000 00000 Completed Generating Revenue
5. Convertible Debt 20-Jul-2016 00000 00000 Completed Generating Revenue
4. Grant 01-Sep-2015 00000 Completed Generating Revenue
3. Grant 24-Jul-2014 00.000 Completed Generating Revenue
2. Accelerator/Incubator 25-Jun-2014 Completed Generating Revenue
1. Grant 15-Jun-2013 $100K Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

AsclepiX Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Barer & Son Capital Venture Capital Minority 000 0000 000000 0
Piedmont Capital Partners Merchant Banking Firm Minority 000 0000 000000 0
Rapha Capital Management Corporation Minority 000 0000 000000 0
Salem Partners Investment Bank Minority 000 0000 000000 0
TCP Venture Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

AsclepiX Therapeutics Executive Team (3)

Name Title Board
Seat
Contact
Info
Wendy Perrow Chief Executive Officer & Board Member
Jordan Green Ph.D Co-Founder, Board Member & Chief Technology Officer
Aleksander Popel Ph.D Co-Founder, Board Member & Chief Scientific Officer

AsclepiX Therapeutics Board Members (1)

Name Representing Role Since Contact
Info
Wendy Perrow AsclepiX Therapeutics Chief Executive Officer & Board Member 000 0000